Literature DB >> 31512188

Understanding the Context of High- and Low-Testosterone Prescribing Facilities in the Veterans Health Administration (VHA): a Qualitative Study.

Guneet K Jasuja1,2, Ryann L Engle3, Avy Skolnik4, Adam J Rose5, Alexandra Male3, Joel I Reisman4, Barbara G Bokhour4,6.   

Abstract

BACKGROUND: Inappropriate testosterone use and variations in testosterone prescribing patterns exist in the Veterans Health Administration (VHA) despite the presence of clinical guidelines.
OBJECTIVE: We examined system and clinician factors that contribute to patterns of potentially inappropriate testosterone prescribing in VHA.
DESIGN: Qualitative study using a positive deviance approach to understand practice variation in high- and low-testosterone prescribing sites. PARTICIPANTS: Twenty-two interview participants included primary care and specialty clinicians, key opinion leaders, and pharmacists at 3 high- and 3 low-testosterone prescribing sites. APPROACH: Semi-structured phone interviews were conducted, transcribed, and coded using a priori theoretical constructs and emergent themes. Case studies were developed for each site and a cross-case matrix was created to evaluate variation across high- and low-prescribing sites. KEY
RESULTS: We identified four system-level domains related to variation in testosterone prescribing: organizational structures and processes specific to testosterone prescribing, availability of local guidance on testosterone prescribing, well-defined dissemination process for local testosterone polices, and engagement in best practices related to testosterone prescribing. Two clinician-level domains were also identified, specifically, structured initial testosterone prescribing process and specified follow-up testosterone prescribing process. High- and low-testosterone prescribing sites systematically varied in the four system-level domains, while the clinician-level domains looked similar across all sites. The third high-prescribing site was unusual in that it exhibited the four domains similar to the 3 low-prescribing sites at the time of our visit. This site had greatly reduced its prescribing of testosterone in the interim.
CONCLUSIONS: Findings suggest that local organizational factors play an important role in influencing prescribing. Sites have the potential to transform their utilization patterns by providing access to specialty care expertise, an electronic health record-based system to facilitate guideline-concordant prescribing, well-defined dissemination processes for information, guidance from multiple sources, and clarity regarding best practices for prescribing.

Entities:  

Keywords:  prescribing; qualitative; system factors; testosterone

Mesh:

Substances:

Year:  2019        PMID: 31512188      PMCID: PMC6848590          DOI: 10.1007/s11606-019-05270-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  28 in total

1.  Clinical practice patterns in the assessment and management of low testosterone in men: an international survey of endocrinologists.

Authors:  Mathis Grossmann; Bradley D Anawalt; Frederick C W Wu
Journal:  Clin Endocrinol (Oxf)       Date:  2014-09-24       Impact factor: 3.478

2.  Factors Influencing Antibiotic-Prescribing Decisions Among Inpatient Physicians: A Qualitative Investigation.

Authors:  Daniel Livorsi; Amber Comer; Marianne S Matthias; Eli N Perencevich; Matthew J Bair
Journal:  Infect Control Hosp Epidemiol       Date:  2015-06-16       Impact factor: 3.254

3.  Who Gets Testosterone? Patient Characteristics Associated with Testosterone Prescribing in the Veteran Affairs System: a Cross-Sectional Study.

Authors:  Guneet K Jasuja; Shalender Bhasin; Joel I Reisman; Joseph T Hanlon; Donald R Miller; Anthony P Morreale; Leonard M Pogach; Francesca E Cunningham; Angela Park; Dan R Berlowitz; Adam J Rose
Journal:  J Gen Intern Med       Date:  2016-12-19       Impact factor: 5.128

4.  American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update.

Authors:  Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau
Journal:  Endocr Pract       Date:  2002 Nov-Dec       Impact factor: 3.443

5.  Barriers to guideline-concordant antibiotic use among inpatient physicians: A case vignette qualitative study.

Authors:  Daniel Livorsi; Amber R Comer; Marianne S Matthias; Eli N Perencevich; Matthew J Bair
Journal:  J Hosp Med       Date:  2015-10-06       Impact factor: 2.960

Review 6.  Patterns of testosterone prescription overuse.

Authors:  Guneet K Jasuja; Shalender Bhasin; Adam J Rose
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-06       Impact factor: 3.626

7.  Disruptive Innovation: Implementation of Electronic Consultations in a Veterans Affairs Health Care System.

Authors:  Gouri Gupte; Varsha Vimalananda; Steven R Simon; Katerina DeVito; Justice Clark; Jay D Orlander
Journal:  JMIR Med Inform       Date:  2016-02-12

8.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.

Authors:  Bruno Lunenfeld; George Mskhalaya; Michael Zitzmann; Stefan Arver; Svetlana Kalinchenko; Yuliya Tishova; Abraham Morgentaler
Journal:  Aging Male       Date:  2015-02-06       Impact factor: 5.892

9.  Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers.

Authors:  Tord Forsner; Johan Hansson; Mats Brommels; Anna Aberg Wistedt; Yvonne Forsell
Journal:  BMC Psychiatry       Date:  2010-01-20       Impact factor: 3.630

Review 10.  Testosterone therapy in the new era of Food and Drug Administration oversight.

Authors:  Bethany Desroches; Taylor P Kohn; Charles Welliver; Alexander W Pastuszak
Journal:  Transl Androl Urol       Date:  2016-04
View more
  1 in total

Review 1.  Positive deviance in health and medical research on individual level outcomes - a review of methodology.

Authors:  Byron A Foster; Kylie Seeley; Melinda Davis; Janne Boone-Heinonen
Journal:  Ann Epidemiol       Date:  2021-12-14       Impact factor: 6.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.